TrialBMC pulmonary medicine2021

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.

Masato Muraki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.